1-3 of 3
Alev Akyol
Close
Sort by
Journal Articles

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Clinical Trials & Observations
Pier Luigi Zinzani, Gilles Salles, Alison J. Moskowitz, Armando Santoro, Amitkumar Mehta, Paul M. Barr, Neha Mehta-Shah, Graham P. Collins, Stephen M. Ansell, Joshua D. Brody, Eva Domingo-Domenech, Nathalie A. Johnson, David Cunningham, Silvia Ferrari, Julie Lisano, Jennifer Krajewski, Rachael Wen, Alev Akyol, Russell Crowe, Kerry J. Savage
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2400–2404.
https://doi.org/10.1182/bloodadvances.2023011030
Published: 2024
Includes: Supplemental data
Journal Articles

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

Clinical Trials & Observations
Stephen M. Ansell, Paul J. Bröckelmann, Gottfried von Keudell, Hun Ju Lee, Armando Santoro, Pier Luigi Zinzani, Graham P. Collins, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Mariano Provencio, Ulrich Jäger, Wolfgang Willenbacher, Rachael Wen, Alev Akyol, Joanna Mikita-Geoffroy, Margaret A. Shipp, Andreas Engert, Philippe Armand
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6266–6274.
https://doi.org/10.1182/bloodadvances.2023010334
Published: 2023
Includes: Supplemental data
Journal Articles

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

Clinical Trials & Observations
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John Kuruvilla, David Cunningham, Justin Kline, Nathalie A. Johnson, Neha Mehta-Shah, Julie Lisano, Rachael Wen, Alev Akyol, Alison J. Moskowitz
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5272–5280.
https://doi.org/10.1182/bloodadvances.2023010254
Published: 2023
Includes: Supplemental data